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Dedicated to the patients suffering from Mastocytosis 
  
  
  
ABSTRACT 
Mast cells are sentinels of danger but they are also the major effector cells in allergic disease 
causing the well-known allergic symptoms caused by their mediators such as histamine and 
prostaglandin D2 that are released upon activation. Mastocytosis is a disease characterized by 
the clonal expansion of mast cells in the skin and/or other organs where the patients suffer 
from mediator-related symptoms and/or organ failure due to mast cell infiltration. The aim of 
the work presented in this thesis was to investigate mast cell function in health and disease, 
particularly systemic mastocytosis. 
In paper I, we investigate the in vivo reactvitiy of mast cells in patients with mastocytosis. We 
show that though the patients with systemic mastocytosis have increased levels of circulating 
mast cell mediators their mast cells in skin and lung are no more reactive then those in 
heatlhy controls. 
Paper II. We analyze the reactivity of in vitro cultured mast cells from the patients 
investigated in paper I, and could show that systemic mastocytosis mast cells  proliferate and 
develop normally though with increased expression of the high affinity IgE receptor.  Mast 
cells from patients with systemic mastocytosis are more reactive to increased osmolarity by 
releasing more PGD2. Investigating the genetic background of mastocytosis we discovered 
that they exhibit a specific miRNA profile.  
In the search for new therapeutical possibilities for mastocytosis we investigated the 
combination of ABT-737, a BH3 mimetic, and Roscovitine in paper III. By targeting 
expression and function of pro-survival proteins we found that even in very low doses the 
drugs induce apoptosis in mast cells carrying the D816V KIT mutation.  
Paper IV. Histone deacetylase inhibitors (HDACi) alter genetic expression. Here we show 
that SAHA, a class II HDACi induces mast cell apoptosis in cell lines and primary systemic 
mastocytosis patient cells, and that KIT is epigenetically silenced by SAHA in KIT D816V 
mutated cells. 
We have previously shown that IgE-receptor cross linking induces mast cell degranulation 
and activation-induced cell survival. In paper V we further investigate the effects of the Bcl-2 
family and found that Bfl-1 is vital for the cell to survive, reform and be ready to degranulate 
again. Patients with allergic disease or cutaneous inflammatory skin disease have increased 
expression of Bfl-1 in their skin mast cells suggesting that targeting Bfl-1 might be an option 
for treatment. 
Paper VI. Further investigating the function of the A1/Bfl-1 gene, we found that knockdown 
of A1/Bfl-1 in mice protects the animals from passive cutaneous and systemic anaphylaxis. 
Additionally, connective tissue mast cells depend on A1/Bfl-1 for their development and 
survival.  
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1. INTRODUCTION 
1.1 THE MAST CELL 
Mast cells are watchmen of the body responding quickly to danger signals by releasing a 
cocktail of mediators in order to activate neighboring cells and to recruit and activate the 
proper combatants of the immune system. They are highly conserved in both function and 
morphology, found in all species of vertebrates and originated about 450 million years ago 
(1). Though mast cells are a very important part of the immune system they are notorious for 
their involvement in asthma and allergy. First described in the thesis of Paul Erlich in 1878 
and since then mostly studied for their harmful effects we now know that they are also 
protective;  truly the “Dr Jekyll and mr Hyde” of the human body (2). 
1.1.1 Mast cells in health and disease 
Mast cells reside in all tissues but predominantly in tissues that form boundaries to the 
surrounding environment as for example skin, lung and intestines (3, 4). At this position mast 
cells easily sense when the body borders have been breached and can act accordingly. The 
human body is constantly under attack from pathogens that could be harmful for us if they 
were let to roam free, and the immune system has developed in order to defeat pathogens as 
well as monitoring the body for signs of disturbances in the overall homeostasis. The immune 
system is divided into two parts of equal importance. The innate immune system is the first 
line of defense consisting of both mechanical barriers like the skin and mucosa as well as 
immune cells like mast cells, basophils and phagocytes. They have no memory of their own 
but express a wide variety of sensors that can detect an extensive range of danger signals. 
They can attack and destroy the invasive pathogens but also attract cells of the adaptive 
immune system. These cells, B and T lymphocytes, will respond by antibody production or 
with cellular responses. Mast cells bridge the innate and adaptive immunity by responding to 
the invasive pathogens and recruiting leukocytes to the place of infestation (5, 6). For 
example mast cells have the capacity to recognize bacteria by a wide range of pattern 
recognition receptors (7, 8). They can respond by releasing chemokines which recruit 
neutrophils into the inflamed tissue (9, 10).  Many studies have shown that mast cells are vital 
in fighting peritoneal infections that otherwise may end in sepsis (11, 12). Many other stimuli 
caused by for example cell injury or cell stress leads to the release of mast cell  mediators (13, 
14) . The mast cell mediators can under these circumstances help with the healing of the 
damaged tissues (15). Other danger signals that activate mast cells are changes in the basic 
body homeostasis like temperature, pressure, pH or osmolarity (16). In spite of all their good 
sides mast cells are notorious for their fundamental role in asthma and allergy (17). Allergic 
diseases include rhinitis, allergic asthma, food allergy and atopic dermatitis. When antigens 
enters the body the patient quickly suffers from acute symptoms like itch, swelling and 
mucus production. Why a harmless protein/antigen can cause a Th2 driven immune response 
resulting in plasma cells producing IgE specific to the protein we do not know. But when the 
IgE is in circulation it will bind to the high-affinity IgE-receptors, FcεRI, on mast cells and 
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basophils. The next time the antigen enter the body the IgE sensitized cells will be activate 
and  release mediators which will instead of fighting an infection cause both the acute 
symptoms and in the long-term lead to tissue remodeling and chronic inflammation. 
1.1.2 Development 
Mast cells originate from hematopoietic stem cells that emerge from the bone marrow and the 
early mast cell progenitors home into the tissue. (18) Mast cell homeostasis is carefully 
monitored since any increase in mast cell numbers is potentially harmful for the tissues. The 
mechanism of how mast cell migration is initiated and performed is not entirely understood. 
However α4β7 integrins have been shown to play a central role in tissue homing in mice 
interacting with endothelial VCAM-1 (19). Chemokines and their receptors also play a 
pivotal role in MCp transfer, for example human cord blood MCps express CCR3, CCR5, 
CXCR2 and CXCR4 (20). Chemotaxis could also be influenced by how inflamed tissues 
attract MCps. Patients with allergic asthma have increased numbers of mast cells in the lungs 
that express chemokine receptors CCR1 and CCR4(21). 
Once mast cell progenitors enter the tissue they mature under the influence of the 
microenvironment.  The surrounding cells secrete cytokines important for the maturation. 
Fibroblasts, stromal cells, endothelial cells and keratinocytes all produce stem cell factor 
(SCF) which is essential for the growth and differentiation of mast cells (22-25). SCF binds 
to the KIT receptor on the mast cell inducing phosphorylation of tyrosine kinases leading to a 
cascade of phosphorylation of the downstream targets including PI3K, MAPK and 
JAK/STAT (26). Mast cells express receptors for numerous cytokines notably it is the typical 
Th2 cytokines IL-3, IL-5, IL-6, IL-9 that drive mast cell differentiation while Th1cytokines 
are inhibitory (20, 27, 28). Since the differentiation is so dependent on the secretion of 
cytokines from the surrounding cells it is not hard to imagine the vast heterogeneity of the 
mast cells within the body and even within the same organ (29, 30). They may vary in size, 
granulation and granular content. Maturating mast cells are packed with secretory granules 
which slowly fill with a variety of mediators. Human mast cells are basically divided into two 
groups, those that store tryptase in their granules (MCT) and mast cells containing both 
tryptase and chymase (MCTC) (31, 32). MCTs are found in submucosal tissues and in healthy 
lungs while the MCTC subtype is dominantly found in skin (33). In Eosinophilic esophagitis 
mast cells expressing only tryptase and carboxypeptidase A contribute significantly to the 
disease, which show that there is greater heterogeneity in mast cells than the mere two groups 
(34).  In the murine system mast cells are also divided into two groups; the mucosal and 
connective tissue mast cells (35, 36). Mucosal mast cells are found in the mucosal tissue in 
low numbers in healthy mice (37). During an infection thought there is a drastic increase in 
MMC numbers. MMCs in the gut mainly produce two types of β chymases, mouse mast cell 
protease 1 and 2 (38). Connective tissue mast cells however are predominantly found in the 
skin. They are long lived with very low turnover. They express two different chymases 
(mMCP-4 and 5) but also two tryptases (mMCP-6 and 7) as well as MC-CPA (39). This is a 
general division and in real life mast cells are highly heterogenic and the protease expression 
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varies due to the tissue and even tissue localization, e.g., tracheal mast cells of both subtypes 
produce six serine proteases as well as carboxypeptidase-A3 (40).  
1.1.3 The KIT receptor and downstream signaling  pathways   
The human KIT gene is located on chromosome 4q11-12 and is expressed in two isoforms 
(41). The isoforms differ in the presence or absence of a specific amino acid sequence 
(GNNK) in the extracellular domain. The splice variants differ in biological activity where 
the GNNK- gives rise to stronger receptor phosphorylation and internalization, and down-
stream MAPK phosphorylation (42). In normal mast cells the isoforms are coexpressed but in 
neoplastic mast cells the GNNK- receptor is domineering (43). The combination of the KIT 
mutation D816V and the GNNK- transcript increase the proliferation which can in turn 
influence the treatment response. The KIT gene is highly conserved over species barriers 
(44). It is a type III tyrosine kinase receptor consisting of an extracellular part containing five 
immunoglobulin-like motifs, a trans membrane segment and an intracellular section where 
the kinase domains and activation loop are situated (45). It is the kinase domains and 
activation loop that catalyze the relocation of a phosphate group from ATP to the substrate. 
One SCF dimer binds to two KIT monomers resulting in receptor homo-dimerization and 
auto-phosphorylation on tyrosine residues. Upon tyrosine phosphorylation the receptor is 
internalized. The binding of adaptor proteins Grb2 will not only transfer the activation signal 
but also recruit Cbl leading to ubiqintation and degradation of the receptor (46). SHP1 and 2 
can inhibit the function of KIT by binding to the phosphorylated residues, thus blocking 
downstream signal transduction (47, 48). PKC inhibit the activity of the KIT receptor by the 
phosphorylation of the kinase region (49). Slug has been identified as a direct transcriptional 
repressor of KIT (50). Interestingly there is a high turnover of the KIT receptor even without 
ligand-receptor interaction (51). Activation of the KIT receptor will initiate many regulatory 
pathways.  
The phosphoinoside 3ˈ-kinase (PI3K) pathway starts with the translocation of PI3K to the 
plasma membrane where it docks to tyrosine residue 721 using the SH2 domain (52). This 
will activate PIP3 in the plasma membrane that will anchor Akt to be phosphorylated by 
PDK1/2 (53-55). Once activated Akt can phosphorylate a large number of substrates. It will 
directly activate mTOR which leads to G1 cell cycle progression and cell proliferation (56). 
Akt can also phosphorylate and activate MDM2, a negative regulator of tumor-suppressor 
gene p53. By similar indirect manor NFκB is activated. Activated Akt will inhibit apoptosis 
by disarming proapoptotic Bim in two steps; inhibition of transcription by inactivation of the 
Forkhead transcription factors FOXO1a and FOXO3a and by direct phosphorylation of Bim 
(57). Akt also inactivate pro-apoptotic proteins like Bad and Bax (58, 59). GSK3β is 
inactivated by AKT leading to the accumulation of cyclin D1 and cell proliferation. The PI3K 
pathway is negatively regulated by the PIP3 phosphateses SHIP1/2 and PTEN which will 
convert PIP3 to PIP2 (60, 61). 
The Janus kinase 2 (JAK2) is constituently associated to KIT and is promptly phosphorylated 
by SCF binding (62). STAT5 will dock to the phosphorylated tyrosine residue via their SH2 
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domain (63).  JAK2 will then phosphorylate STAT5 allowing for them to dimerise. STAT 
dimers enter the nucleus where it will bind to specific gene promoters and direct 
transcription. Genes that are regulated by STAT5 include for example GATA2 and Bcl-XL 
that drive cell proliferation, development and survival (64, 65). The JAK7STAT pathway is 
quickly activated but also short lived. Once the STAT dimers are formed they are targets of 
tyrosine phosphatases, as is phosphorylated JAK (66). SOCS3 inhibit the pathway by binding 
to the phosphorylated JAK marking it for degradation (67). PIAS proteins on the other hand 
will inhibit STAT5 action at the transcription site (68).  
Using adaptor proteins binding to the SH2 domain, the RAS/MAPK pathway is activated 
(69). The adaptor protein Grb2 binds directly to tyrosine residues in the KIT receptor. It 
forms a complex with guanine exchange factor Sos, which in turn activates the membrane 
bound protein RAS (70).  Activated RAS will in turn activate MAP3K Raf directing 
phosphorylation of MAPKK MEK and then MAPK ERK1/2 (71).  Phosphorylated Erk 1/2 
may translocate to the nucleus or stay in the cytoplasm depending on the substrates (72). In 
fact there are hundreds of substrates through which ERK have numerous ways to influence 
cellular proliferation and survival.  
The Src tyrosine kinases Fyn and Lyn are yet another pathway in which KIT signaling is 
transferred (73). They express SH2 domains which interact with the phosphorylated tyrosine 
residues on the KIT receptor. Activated Src kinases will initiate PI3K, JAK/STAT and the 
RAS/MAPK pathways. They have shown to be important in mast cell proliferation and 
chemotaxis (74). Mast cells harboring the D816V mutation are largely independent of Src 
activation (75). 
 
 
Figure 1, The activation pathways of the KIT receptor. SCF binding to the KIT receptor 
will activate a downstream cascade of phosphorylation, initiating transcription of survival and 
proliferation genes and inhibiting pro-apoptotic proteins.   
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1.1.4 Mast cell mediator release 
Mast cells can be activated by a wide variety of stimuli and they may respond in many ways. 
Within seconds upon activation, e.g., through the high affinity IgE-receptor, mast cells can 
release the content of their preformed secretory granules. Receptor activation leads to 
cytoskeletal rearrangement and microtubule formation (76, 77). The granule slide along the 
tubule and when they reach the plasma membrane they fuse first with each other and then 
with the outer membrane to spill the content into the extracellular space (78, 79). Mast cells 
can also produce and secrete lipid mediators. Activation of Phospholipase A2 initiates the 
release of arachidonic acid from the cell membrane (80). Via the cyclooxygenase pathway 
prostaglandins are produced. Mast cells predominantly produce prostaglandin D2 (PGD2) 
upon activation though they may also produce PGE2 (81). The prostaglandins are transported 
out of the cells via the multidrug resistance protein 4 and possibly other transporter proteins 
(82). Through the lipoxygenase pathway arachidonic acid is converted into the lipoxygenase 
(LT)  pathway generating LTB4 and  the  cysteinyl leukotriens LTC4, D4 and E4 (83). Mast 
cells can also produce cytokines and chemokines in response to stimulation.  Thus, some 
cytokines and chemokines are stored in the secretory granules and subsequently released 
within seconds of degranulation (84, 85), while other cytokines are newly synthesized as a 
response to stimulation.  
1.1.5 FcεRI activation 
The most excessive studied pathway for mast cell activation is through the high affinity 
immunoglobulin E receptor FcεRI. The receptor is composed of four subunits, the 
extracellular, transmembrane bound α unit, the β unit which cross the membrane four times 
and the two γ units which are bound by a disulfide bond and mediates the intracellular 
signaling (86, 87). The extracellular part of the α-unit contains two binding domains for the 
heavy chain of the IgE molecule. When the cell-surface bound IgE recognize a multivalent 
antigen the receptors aggregate and become cross-linked.  The receptor-IgE-antigen complex 
is internalized setting of the activation cascade resulting in cytoskeletal rearrangement, 
expulsion of granules and secretion of lipid mediators and cytokines (88). Once mast cells 
have been activated some of them have the unique capacity to survive and regranulate and 
thus be ready to be reactivated within a short space of time (89).  
1.1.6 Mast cell mediators 
Mast cells have the ability to produce and release numerous mediators depending on the 
stimulation (39). Histamine is formed from histidine by the enzyme L-histidine 
decarboxylase and is stored in the secretory granules (90). It is released upon activation like 
FcεRI crosslinking and bind to the histamine receptors H1-H4 on diverse cells and tissues 
(91). Histamine is a powerful mediator with many effects, e.g. regulating the sleep-wake 
rhythm, wound healing, vasodilation and smooth muscle contraction. Many of the symptoms 
displayed by mast cell associated diseases are a result from histamine release which is why 
antihistamines are widely used.  
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Mast cells produce and store large amounts of proteases which bind and cleave specific 
substrates (32). The proteases produced are non-mast cell specific (e.g. granzymes) and three 
classes of mast cell specific proteases; Tryptase, Chymase and Carboxypeptidase A. Tryptase 
is a neutral serine protease stored in the mast cell granule and released upon activation. There 
are two subgroups αI and II and βI-III. Catalytic active tryptase is stored within the mast cell 
granules and is able to cleave its substrates directly upon release, however mast cells also 
continuously secrete tryptase (92). Neuropeptides, prothrombin, fibrinogen are examples of 
proteins which carry a substrate sequence and are thus degraded by tryptase (93). Tryptase 
also have the ability to activate the PAR-2 receptor on various tissues. PAR-2 activation leads 
to brochodilatation, vascular relaxation and altered gastrointestinal epithelial permeability 
(37, 94, 95). Humans express only one form of chymase and it is almost exclusively found in 
mast cells. In allergic disease chymase augment the effect of histamine on wheal formation 
but it can also degrade danger signals, e.g. IL-33, thus reducing inflammation (96-98). In 
healthy tissue chymase is involved in managing connective tissue homeostasis (99). 
Carboxypeptidase A is stored in mast cell granules in its active form though activation is kept 
low by the suboptimal pH (100). Biological substrates include endothelin-1, angiotensin I and 
sarafotoxin 6. It has been implicated to contribute in anaphylaxis and can be used as a 
diagnostic marker (101).   
Prostaglandin D2 is de novo synthesized by activated mast cells and can cause contraction of 
the airways, regulate body temperature and cause vasodilatation all depending on what tissue 
is activated via binding to the PTGDR (DP1) and CRTH2 (DP2) receptors. The PTGDR 
receptor is associated to asthma and specific groups of disease severity (102). CRTH2 is 
expressed on T cells, basophils and eosinophils among others (103). By activating the 
CRTH2 receptor PGD2 will stimulate migration and the production of Th2 proinflammatory 
cytokines (104). CRTH2 is also expressed on the surface of type 2 innate lymphoid cells, 
these cells are enriched in the nasal polyps of patients suffering from rhinitis (105).  
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1.2 MASTOCYTOSIS  
1.2.1 Introduction 
Mastocytosis is a disease where mast cells accumulate in one or more tissues well beyond 
normal numbers and the cell infiltrate per se as well as the large amount of mediators that 
they release will cause a number of different symptoms (106, 107). The symptoms greatly 
depend on which tissues are affected (107), and range from mast cell mediator symptoms of 
itching, flush and hives, to very general symptoms like nausea, headache and irritability. 
Severe forms of systemic mastocytosis present with symptoms of bone marrow failure with 
cytopenia, weight loss, and subfebrility. The generality of the symptoms can make the 
diagnosis of systemic mastocytosis difficult (108).  The genetics of mastocytosis is to some 
degree investigated; generally there is a mutation in the tyrosine kinase receptor KIT which 
renders the receptor constantly active, independent of its ligand stem cell factor (109). The 
vast majority of cases of systemic mastocytosis are indolent, with a normal life expectancy 
and little effect of quality of life when symptomatic treatment is administered at optimal 
levels. However, there is no available treatment that can remove the aberrant cells and cure 
the patient. There are however many new treatments under investigation (110). Due to the 
mutational alteration of the KIT receptor the first line of tyrosine kinase inhibitors have low 
effect on mastocytosis but there are several new TKIs showing promising effects.  
1.2.2 Genetics 
One single mutation, the exchange of an A to a T at codon 816 changing the amino acid from 
aspartic acid (D) to valine (V) in the kinase domain of the KIT gene, leads to the detrimental 
effect of ligand independent activation (111, 112).  There is no need for SCF to be present 
since the KIT receptor is constantly activated and the mast cell will continue to grow and 
differentiate (113). Although the D816V mutation is by far the most common in systemic 
mastocytosis, other KIT mutations have been described (114-123). Some also located within 
the kinase domain are associated with more severe disease phenotype. Other mutations within 
the KIT gene but outside the activation loop have been described to associate with more 
benign forms of mastocytosis. Recent data show that additional KIT mutations will work 
synergistically with the D816V mutation and worsen the disease prognosis (109). The KIT 
mutations are somatic and thus not hereditary. Interestingly there are reports on familiar cases 
of systemic mastocytosis where a germ line mutation of KIT is present (124). This mutation is 
however not the D816V mutation common in most patients with adult onset.  
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Table 1, Kit mutations associated to different kinds of mastocytosis.  
Kit mutation Location Associated form 
C443Y, C419Y, 
InsFF419, T417Y, 
Y418Y 
Extracellular 
domain 
Cutaneous pediatric mastocytosis 
Del419 Extracellular 
domain 
Familial cutaneous mastocytosis 
Dup(501-502) Extracellular 
domain 
Mast cell leukemia 
K509I Extracellular 
domain 
Familial SM 
A533D Transmembrane 
domain 
Familial cutaneous mastocytosis 
F522C Transmembrane 
domain 
SM 
D572A Juxtamembrane 
domain 
Cutanous pediatric mastocytosis 
V560G Juxtamembrane 
domain 
SM, Familial cutanous mastocytosis 
V559I Juxtamembrane 
domain 
Agressive SM 
R634W Kinase domain Familial cutanous mastocytosis 
InsV815-I816 Kinase domain SM 
D816F, D816H, D816I, 
D816V, D816Y 
Kinase domain SM, Agressive SM, Cutanous pediatric 
mastocytosis, Familial cutanous 
mastocytosis 
I817V Kinase domain SM 
D820G Kinase domain Aggressive SM 
N822I Kinase domain Familial cutaneous mastocytosis 
E839K Kinase domain Maculopapular cutaneous mastocytosis 
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Other heterozygous somatic mutations commonly found in various myeloid hematological 
malignancies have also been found in systemic mastocytosis. Many of these are regulators of 
transcription and epigenetics: TET2 is a tumor suppressor gene which is involved in DNA 
demethylation. Loss of function mutations in the TET2 gene is one of the most frequent non-
Kit mutations in mastocytosis (125). How TET2 contribute to disease progression is debated 
in one cohort it correlates to advanced forms of mastocytosis while in another study no such 
correlation was found (126, 127). By introducing the D816V mutation into TET2 mutated 
mast cells there is an increase of proliferation. Other epigenetic regulators ASXL1 and 
SRSF2 however are associated to poor prognosis not only in mastocytosis but also in other 
malignant myeloid malignancies (128, 129).  The SRSF2-P95 hotspot mutation correlates to 
mastocytosis with associated clonal hematologic non-mast cell lineage diseases showing that 
an alteration of the mRNA splicing machinery in association to a KIT mutation lead to a 
more aggressive disease (130, 131).  Further, epigenetics aberrations have been demonstrated 
in patients with systemic mastocytosis. Global levels of DNA hydroxymethylation in patients 
with mastocytosis would imply that there is the possibility of global destabilization of gene 
expression (132, 133). 
1.2.3 Symptoms 
The symptoms of mastocytosis vary depending on the tissue(s) affected.  In cutaneous 
mastocytosis the skin is the only organ involved and the symptoms are mostly associated to 
the skin. For example itching, blistering and swelling.  In systemic mastocytosis where there 
is mast cell infiltrate various organs the symptoms are greatly diverse. Symptoms can 
manifest chronically or at intervals. Often these attacks can be brought on by certain triggers 
like stress, physical exercise or rapid changes in temperature, also the intake of alcohol, 
certain food or drugs, can bring on an episode. Although the diversity is great almost all 
patient display some form of flushing. We strongly believe that systemic mastocytosis is an 
underdiagnosed disease, due to the fact that most symptoms are quite general like 
gastrointestinal problems, ulcers, heart palpitations, hypotension, osteoporosis/sclerosis, 
sweating, dizziness and headache. Furthermore, psychological symptoms like depression, 
irritation, concentration difficulties and anxiety have been observed.  Sadly patients can live 
many years with undiagnosed and unmanaged disease. Anaphylaxis is a severe and rapid 
incident where the mast cell mediators bring on systemic vasodilatation causing a rapid blood 
pressure drop, often ending in syncope. Patients with systemic mastocytosis have a 1000 fold 
increased risk anaphylaxis compared to the general population. The experience from the 
mastocytosis center at Karolinska university hospital is that hymenoptera sting is frequently 
the anaphylaxis trigger (125, 126). Interestingly, there is no direct correlation between mast 
cell burden and degree of clinical symptoms (127). On the contrary, some patients suffer 
greatly from mediator symptoms yet there is no detectable mast cell increase, while other 
patients have massive mast cell infiltration in an organ but rather mild or even no symptoms. 
This has spurred the hypothesis that systemic mastocytosis mast cells are somehow more 
reactive, however this hypothesis has not been proven. 
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1.2.4 Diagnosis 
Cutaneous mastocytosis is diagnosed from the visual skin symptoms and positive Darier sign 
(128). However skin biopsy can be used to determine the level of mast cell infiltration. 
Systemic mastocytosis cannot be diagnosed on the symptoms alone, but needs a biopsy of an 
involved organ (not skin), frequently bone marrow. In 2001 a consensus report was published 
presenting standardized diagnosis criteria to ensure correct evaluation of patients (129). The 
diagnosis criteria including one major and three minor; the major being presence of mast cell 
aggregate of 15 or more cells in the bone marrow or other organ however not the skin. The 
minor criteria are: A) more than 25% of the mast cells have abnormal spindle shaped 
morphology; B)   CD117 positive cells also express CD2 and/or CD25; C) elevated levels of 
serum tryptase (>20 ng/ml);  D) presence of the D816V KIT mutation, detected either in 
blood or tissue. If the major and one minor criteria or three of the minor criteria are fulfilled 
the patient is diagnosed with systemic mastocytosis.  
 
Figure 2, Examples of diagnostic histological staining of bone marrow. A) Tryptase 
staining show a mast cell aggregate of >15 mast cells. B) CD25 staining of the same 
infiltrate. Credit Igor Schliemann 
1.2.5 Forms of mastocytosis and disease progression 
There are three main forms of CM, maculopapular cutaneous lesions where brown spots 
appear on the skin where the mast cells aggregate, mastocytoma where the mast cells 
aggregate to one spot forming a lump, and diffuse cutaneous mastocytosis where mast cells 
infiltrate the entire skin (128). The typical maculupapular cutaneous lesions are divided into 
two subgroups. The monomorphic variant where small maculopapular lesions are found and 
the polymorphic variant where the lesions are larger and the shape and size are varied.  
Cutaneous mastocytosis of the polymorphic variant mainly affect children and the disease 
resolve itself at or just after puberty (130, 131). Some children exhibit the small 
maculopapular lesions commonly found in adults. These children often carry the disease into 
adulthood and develop systemic mastocytosis (132). Diffuse cutaneous mastocytosis is very 
rare (133). The children have no individual lesions rather a general mast cell infiltration of the 
entire skin. Their skin is thicker and prone to blistering even from mild irritation.  
Mastocytoma patients exhibit one or more large, brown nodules (134). They may display 
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symptoms like flushing, swelling and itch when the lesion is rubbed however patients may be 
entirely asymptomatic. Adult onset CM has a good prognosis but still reduce the quality of 
life of the patients from both cosmetic reasons and due to the skin irritation (128). 
In systemic mastocytosis at least one organ other than the skin is involved, most often the 
bone marrow (129).  Patients with the most common form of SM, indolent systemic 
mastocytosis (ISM) have low mast cell burden (135). The prognosis is good with normal life 
expectancy and high quality of life as long as symptoms are well managed. Some patients 
with the indolent form however develop a more aggressive disease over time. Detecting these 
patients prove a great challenge since most of them have the same KIT mutation. Many 
attempts have been made to find biomarkers identifying the patients who are at risk of disease 
development. So far elevated levels of IL-6 at the time of diagnosis associate with the 
progress of advanced disease in the future (136, 137). In systemic mastocytosis with 
associated hematologic neoplasm (SM-AHN) the symptoms and prognosis differ greatly 
depending on the associated disease (138). The associated disease is often of a myeloid origin 
as acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) though it 
can be any hematologic malignancy (139). Both malignant components usually share 
common genetic abnormalities such as the activating KIT mutation or other mutations (140). 
TET2, SRSF2 and ASXL1 are frequently mutated in SM-AHN, recent investigations show 
these mutations precede the KIT mutation and that the presence of ASXL1 mutations 
associates to worsen outcome (141, 142). In the rare form aggressive systemic mastocytosis 
(ASM) the prognosis is poor since treatment options are few (143).  In ASM there is often a 
considerate infiltration of mast cells in different tissues with resulting organ failure. Almost 
any organ may be affected but most commonly are the bone marrow and skeletal system, but 
also the liver, spleen and GI tract are frequently affected. The median survival is two to four 
years. However, ASM can develop into mast cell leukemia with dismal prognosis. In mast 
cell leukemia there is a rapid expansion of mast cell in many tissues, even in peripheral 
blood, and the prognosis is very bad with approximately six months survival (144, 145). It 
can be preceded by advanced forms of mastocytosis or be a de novo event. Interestingly mast 
cell leukemia is less frequently displaying the D816V KIT mutation; in fact there is a 
subgroup of patients with no KIT mutation at all  (145). In mast cell sarcoma 
morphologically atypical mast cells form a large tumor which rapidly grow destroying the 
surrounding tissue (146, 147). It is a very rare disease with poor prognosis. Some patients 
have had pediatric mastocytosis which then has transformed into sarcoma but most are adult 
onset. Some sarcomas have the D816V mutation but it is not universal.  
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Figure 3, Representative skin changes. Maculopapular cutaneous lesions in adult patients 
with mastocytosis. Credit Theo Gülen 
1.2.6 Treatment  
Presently there is no curative treatment for systemic mastocytosis (110, 148). For most 
patients, the disease is indolent without progression, and with a normal life expectancy, and 
m tanagement of the symptoms is  the key. Assymptoms vary so greatly between patients 
there is no straight line of treatment for all patients. Antihistamins are used to alleviate 
symptoms like pruritus and flushing (149, 150). H1 antihistamines are a diverse group of 
molecules which all block the H1 receptor on target cells thus inhibiting the reaction. The 
large variety of H1R-blockers makes it easier to fine-tune the therapy for each patient. H2 
receptor blockers mainly target cells in the GI tract and is used to treat gastric hypersecretion 
and peptic ulcers. Ultraviolet light can alleviate symptoms of cutaneous mastocytosis (151). 
Both the lesions and the pruritus are significantly reduced by UV treatment however this 
treatment is in itself is carcinogenous and should be used with caution. Sodium cromoglycate 
effectively reduces gastrointestinal problems (152, 153). It stabilizes the mast cells by 
blocking calcium influx and thus degranulation. Leukotriene antagonists block the activation 
of leokotrien receptors on, e.g., smooth muscle cells. This may reduce respiratory and gastro 
intestinal symptoms (154). Omalizumab, a humanized monoclonal anti IgE antibody, has 
been used to alleviate symptoms in some patients with varying results (155, 156).  More 
aggressive forms of systemic mastocytosis are met with more aggressive forms of treatment 
where the goal is to reduce the cell burden. Interferon α can reduce the mast cell burden and 
seem to somewhat stabilize the cells however there are severe side effects (157). Lower doses 
of interferon alfa in combination with high dose corticosteroids are more frequently used. 
Cladribine is a purine analogue shown to initiate remission but can also induce severe 
myelosupression (158). Hematopoietic stem cell transplant can be effective in aggressive 
systemic mastocytosis, yet only younger patients are eligible (159). 
1.2.7 Drugs in research 
The need for better drugs inspire the field to do intensive research on finding new effective 
drugs that can actually treat the patients instead of merely manage the symptoms. The finding 
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that tyrosine kinase inhibitor imatinib was immensely effective in treatment of CML brought 
the hope that it could also be used to treat systemic mastocytosis. Mast cells with the KIT 
mutation D816V are resistant to imatinib due to structural changes brought on by the 
mutation (160). However, other kinds of tyrosine kinase inhibitors are under clinical 
investigation. Midostaurin is a TKI which have been shown to downregulate KIT 
autophosphorylation in mast cells with mutated KIT which are resistant to Imatinib (161). It 
has shown very promising results in clinical trials (162, 163). A majority of patients display 
reduced mast cell number in the bone marrow as well as serum tryptase levels even in very 
aggressive forms of MCL. Dasatinib is another TKI which induces apoptosis in KIT mutated 
mast cells and have shown promising result in clinical trial (164, 165).  There are numerous 
other TKIs used mainly for research, the difficulty is to find a TKI that specifically target 
mutated KIT. Interestingly each KIT mutation will influence the morphology and activity of 
the receptor and thus alter the response to TKIs (166). By screening a library of small 
molecules BLU-285 was found to specifically inhibit KIT with the D816V mutation. It is 
presently in phase one clinical trial for treatment of advanced systemic mastocytosis, no 
NCT02561988.   
Other targets downstream of the KIT activation pathway can be targeted by small molecular 
inhibitors. The JAK/STAT pathway is activated by phosphorylated KIT stimulating increased 
proliferation. The JAK/STAT pathway is also an important part of signal transduction in 
many cytokine receptors. JAK inhibitors have recently been tested in a few patients with 
advanced mastocytosis (167, 168). The resulting reduction of symptom burden was 
significant as was the increase of quality of life, however little or no reduction of mast cells or 
serum tryptase levels were seen. The PI3K pathway also contains numerous promising 
targets. Pan inhibition of PI3K itself is associated with high toxicity but has shown to inhibit 
proliferation of mutated mast cells in a murine model (169). Idelalisib is a new PI3K inhibitor 
targeting the active subunit preferential in hematologic neoplasms and it has been shown to 
be very effective in the treatment of CLL (170). Another second generation PI3K inhibitor 
LY294002 successfully inhibit proliferation in KIT mutated mononuclear cells (171). mTor a 
downstream target of the PI3K pathway is upregulated in neoplastic mast cells and inhibition 
of mTor induces apoptosis in KIT mutated mast cells in vitro (172, 173). However the first 
clinical trial of the usage of an mTor inhibitor in treatment of systemic mastocytosis failed to 
show clinical relevance (174). To increase efficacy dual inhibitors targeting PI3K and mTor 
simultaneously has been developed. The dual PI3-kinase/mTOR blocker NVP-
BEZ235 currently in multiple clinical trials has been shown to induce apoptosis in human 
mast cell lines 1.1 and 1.2 (175). The effect on mast cell survival is even more pronounced 
when combined with Stat-5 inhibition (176). Akt is the dominant actor in the PI3K pathway 
and several AKT inhibitors have been developed and is in clinical trials, however, they have 
not yet been tested in mast cells (177). Small molecular inhibitors can also be utilized in 
targeting the Bcl-2 family members. They are proteins regulating cell survival and apoptosis 
via intricate homeostasis. Obatoclax was the first pan inhibitor of the Bcl-2 family to be 
introduced in clinical trial. It has been shown to induce apoptosis in mastocytosis cell lines 
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alone and in synergistic effect with a tyrosine kinase inhibitor (PKC412). Our group has 
investigated the effect of ABT-737, a BH3 mimetic, inhibiting Bcl-2, Bcl-XL and Bcl-w that 
effectively induces apoptosis in mast cells (178). In paper IV we show that it works 
synergistically with the Mcl-1 inhibitor Roscovitine to induce apoptosis in KIT mutated mast 
cells. 
Another way to attack the mast cells is to target surface markers which are expressed by 
neoplastic mast cells. CD123, the alpha chain of the IL-3 receptor, is expressed on some 
aberrant mast cells (179). CD123 can be targeted by SL-401, a molecule where the catalytic 
and tranlocational domains of diphtheria toxin have been fused together with IL-3 (180). It 
would directly target and kill cells expressing CD123. It is presently in clinical trial for usage 
against systemic mastocytosis (no NCT02268253). Antibodies may also be used to target the 
surface molecules. Bretuximab vedotin is an antibody-drug conjugate consisting of chimeric 
antibodies binding CD30 connected to monomethyl auristain E an antimitotic agent. CD30 is 
overexpressed by neoplastic mast cells in many patients with ASM or MCL and the drug has 
been tested in a few patients resulting in a normalization of bone marrow composition (181-
183). Targeting CD52 in vitro induces apoptosis in neoplastic mast cells (184). This short 
description of the research in development of new treatment options for mastocytosis 
indicates the difficulty to treat this heterogeneous disease.   
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1.3 REGULATION OF MAST CELL SURVIVAL AND APOPTOSIS 
1.3.1 Introduction 
The body is an organism in constant development. Cells develop in responds to different 
stimuli and some of them like the tissue residing mast cells will survive for a very long time 
while other cells like the intestinal epithelial cells are constantly renewed. There is a fine 
balance between life and death in the cellular world. This is why it is so strictly monitored by 
multiple control layers. Too much survival will lead to cancer while to little survival lead to 
ischemic and neurodegenerative disease. Apoptosis is controlled cell death where the cell 
follows a specific rout ending in its degradation and engulfment without spilling any internal 
cell substances which could potentially harm the surrounding tissue. Apoptosis is vital in 
normal development but can be detrimental if activated under the wrong circumstances. 
Many of the genes involved in apoptosis regulation are implicated in cancer development 
1.3.2 The Bcl-2 family 
The B-cell lymphoma 2 (Bcl-2) family members are important regulators of cell survival and 
apoptosis (185). The Bcl-2 gene family is consisting of the pro-survival proteins; Bcl-2, Bcl-
xL, Bcl-w, Mcl-1, Bfl-1and the pro-apoptosis proteins divided into the Bax-subfamily and the 
BH3-subfamily.  The pro and anti-apoptotic family members bind to each other in order to 
inhibit the function and block the binding sites of their counterpart (186).  The BH3 only 
family members can inhibit the function of the pro-survival proteins which in turn inhibit the 
effector proteins Bax/Bak. Intracellular stress signals will increase the expression of the pro-
apoptotic and reduce the expression of the pro-survival family members. The pro-apoptosis 
proteins induce mitochondrial membrane permeability and release of cytochrome c into the 
cytoplasm. Together with apoptotic protease activating factor 1 (APAF1) cytochrome c will 
form the apoptosome which then recruit and activate caspase-9 (187).  Active caspase-9 will 
cleave and activate the executioner caspases -3, -6 and -7. They will in turn start cleaving 
cellular content thus starting degradation (188). Inhibitor of apoptosis proteins (IAPs) are the 
last layer of apoptosis regulation (189). They bind to the executioner caspases and inhibit 
them by catalyzing ubiquination and by physically blocking the substrate. 
The Bcl-2 family is vital in regulating mast cell survival and apoptosis. SCF signaling leads 
to increased expression of pro-survival proteins Bcl-2 and Bcl-XL (190).  SCF has been 
shown to regulate mast cells survival by repressing the transcription of Bim and 
phosphorylation of the Bim protein that makes it vulnerable for proteosomal degradation  (57, 
190). Bcl-2 and Bcl-XL have been proven to be essential in the development in murine mast 
cells both in vitro and in vivo (191, 192). Other cytokines are indispensable for mast cell 
survival where Puma as well as Bax and Bak that have been shown to induce apoptosis 
following cytokine deprivation (193, 194).  Alterations of the expression of members in the 
Bcl-2 family can be detected in many forms of cancer. In mastocytosis both Bcl-2 and Bcl-
XL can be detected at higher levels in patient samples (195, 196). Inhibiting pro-survival 
members of the Bcl-2 family using small molecules is a way to induce apoptosis. As 
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previously mentioned our group has investigated the effect of ABT-737 a BH3 mimetic 
inhibiting Bcl-2, Bcl-XL and Bcl-w (178).  
 
Figure 4, Illustration of the Bcl-2 family. There is an intricate balance between the pro and 
anti-apoptotic members of the Bcl-2 family. The increase of Bax and Bak will lead to MOMP 
and the subsequent release of cytochrome C, activation of caspases and apoptosis. Bax/Bak is 
in turn inhibited by the anti-apoptotic Bcl-2 like proteins which are inhibited by BH3 only 
proteins. 
1.3.3 Activation induced survival 
Our group has intensively studied the mechanism for activation-induced mast cell survival. 
When the antigen binds to the IgE molecules on the FcεRI receptor it leads to receptor cross-
linking and the degranulation cascade is induced. Certain mast cells have the ability to 
survive, regranulate and thus be activated again. This is mainly controlled by the Bcl-2 family 
member A1 (197-199). The FcεRI activation leads to the translocation of NFAT from the 
cytosol to the nucleus and the subsequent transcription of A1 (200). Interestingly there is a 
difference in the capability to survival after receptor crosslinking between the two mast cell 
types (201). Investigating the in vitro cultured mast cells mimicking the two subtypes show 
that the short-lived mucosal mast cells have no A1-induction and no increased survival while 
the long lived connective tissue mast cells induce A1 expression and display activation 
induced survival upon IgE receptor cross-linking.  Mice lacking the A1 gene have 
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significantly reduced numbers of connective tissue mast cells and the mice have dramatically 
reduced response to induced anaphylaxis (199). There is a significant upregulation of the 
human homolog Bfl-1 in mast cells in birch-pollen provoked skin (202). Bfl-1 expression is 
induced not only by cross-linking FcεRI but also FcγRI indicating that activation-induced 
survival occurs not only in allergic diseases but also in diseases where IgG is the main 
immunoglobulin (203).  
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1.4 EPIGENETICS  
1.4.1 Introduction 
Each cell of the body contains the same DNA although they have fundamentally different 
commitments. This is because the entire DNA is not active all the time, the same genes are 
not transcribed in all cells and if they are transcribed the amount of protein produced is very 
different. Epigenetics is defined as stably heritable phenotype resulting from changes in a 
chromosome without alterations in the DNA sequence. This involves everything from how 
the DNA sequence is accessible for the transcriptase via the folding of the DNA determining 
the proximity of regulating elements to the DNA sequence of interest to how the mRNA is 
controlled. In 1957 Conrad Hal Waddington founded the metaphor of the epigenetic 
landscape to describe how gene regulation modifies cellular evolution.  In cancer the 
epigenetic regulation is often distorted at all levels. 
1.4.2 DNA structure 
The DNA forms a double helix with strands running in opposite directions (204). The helix is 
wrapped around the nucleosomes 1.65 times (205). The nucleosomes are cores formed by 
two copies of each of the four histones H2A, H2B, H3 and H4 (206). Histones are highly 
alkaline proteins each histone has both a C-terminal and an N-terminal tail. The fifth histone, 
H1, keep the DNA connected to the nucleosome. The nucleosomes fold up the chromosome 
fiber which loops and coils again (207). The chromosome can open and close depending on 
the need for the transcription machinery to access the DNA.  
1.4.3 DNA modifications 
Our genome contains large regions of genetic information that is not supposed to be 
transcribed. They are e.g. pseudogenes, repetitive elements and transposons but also genes 
which are transcribed only during development. These regions are effectively silenced 
without any effect on the surrounding genes by the addition of a methyl group to cytosine 
thus forming 5-methylcytosine (5mC) (208). Methylation of a cytosine nucleotide usually 
occurs when it is followed by a guanine nucleotide, a CpG. They cluster together forming 
CpG islands which often locate in promotor and other regulatory regions. The effect of the 
methylation is a blockade of binding sites for the transcription machinery but also the binding 
of proteins that influence the chromatin structure (209, 210). Demethylation is vital during 
development. Recent discoveries show that thymine DNA glycosylase in collaboration with 
Tet enzymes can transform 5-methylcytosine to form 5-hydroxymethylcytosine (5hmC) (211, 
212). Tet enzymes can further oxidize 5hmC to form 5-formylcytosine (5fC) and 5-
carboxycytosine (5caC) (213). 
1.4.4 Histone modifications  
The N-terminal histone tails protruding from the nucleosome can be chemically modified 
which regulate the availability of the DNA strain (207). Methyl groups are added to the tails 
on histones 3 and 4 by histone methyltransferases while they may be removed using histone 
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demethylases (214, 215).  Methylated histones can either repress or activate transcription 
depending on which of the histone tails are methylated and how many methyl groups are 
transferred. For example adding three methyl groups to H3K9 will bind heterochromatin 
protein 1 continuously closing the DNA for transcription (216). Histone deacetylases and 
transferases move acetyl groups to and from the histone tails (217, 218). Acetyl groups on the 
histone tails will reduce the interaction between the nucleosome and the DNA relaxing the 
DNA (219). Histone deacetylase inhibitors keep the DNA relaxed by inhibiting the removal 
of the acetyl groups (220, 221).  
1.4.5 Micro RNA 
MiRNAs are short sequences of approximately 22 nucleotides. They bind to the targeted 
mRNA sequence retaining them in the cytosol and thus regulating what proteins are in the 
end translated. They were first described in C. Eleganse by dr Ambrose in the beginning of 
the 1990th, however it would take a decade before the field of miRNA research was to gain 
momentum (222). Then the miRNA Let-7 was found to be crucial for developmental timing 
in C. Eleganse (223). The family of Let-7 is unusual in the way that if they are silenced the 
effect on the organism is detrimental (Let=Lethal) (224). 15 years later we now know that 
most miRNAs can be taken out without such massive impact on the organism. They rather 
seem to be guardians of the cell to step into action when the cell is stressed by ex-
environmental factors like changes in osmotic pressure (225). The miRNA mechanism is 
highly conserved found in plants, animals and even in some viruses though with minor 
differences in target recognition (226-228).  
The miRNa genes are often found in introns. They are transcribed by RNA PolII/III and the 
RNA forms a pri-miRNA (229, 230). It is then cleaved into pre-miRNA by the enzyme 
Drosha and DGCR8 and forms a hairpin (231, 232). The hairpin is transported out from the 
nucleus by exportin -5 (233). In the cytoplasm the Dicer and TRBP enzymes cleave of the 
hairpin loop and divide the strands (234). The mature miRNA is then loaded into the RISC 
complex by Ago2 (235). Once located there the miRNA is highly stable (236). When mRNA 
is released from the nucleus it has to pass by a cloud of miRNA-RISC complexes. The 
mRNAs which show a specific target sequence will interact with the miRNA and will be 
retained in the cytosol never to reach the ribosome. There has been a deliberation regarding if 
the mRNA is degraded or only retained for a period. It has been shown that at least to some 
degree the miRNA guide the mRNA to the general eukaryotic machinery for mRNA 
degradation (237, 238).  
Recent studies implicate miRNAs in directing myeloid development (239). Mir-27a has been 
shown to be important in myeloid development. It regulates the expression of GATA2, a 
transcription factor regulating hematopoiesis as well as mast cell development (240, 241). 
The mir-221/222 cluster has the ability to directly target KIT mRNA but has also been shown 
to indirectly inhibit Slug, a negative regulator of KIT (242, 243). In other cell systems KIT is 
directly targeted and down regulated by the mir-221/222 cluster (244). The cluster is 
upregulated upon mast cell activation but seems not to directly influence viability (245). 
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Instead cell cycle inhibitor p27klp1 is the effected target inhibiting proliferation and stem cell 
accumulation. Following studies indicate that mir-221 is a major regulator of mast cell 
effector functions as degranulation and migration due to cytoskeletal deregulation (246). 
Alteration of the mir-221 seed sequence in the KIT 3´UTR correlate with increased risk of 
acral melanoma (247).  Mast cell viability and homeostasis is regulated by mir-146a (248). 
Extensively implicated in allergic diseases Mir-155 is a regulator of mast cell effector 
function by targeting parts of the signal transduction. Mir-155 knockout mice display 
significantly increased passive anaphylaxis due to the alteration of the PI3Kγ pathway (249). 
Anaphylaxis is on the other hand reduced in mir-155 deficient mice in response to IL-10 
treatment via the alteration of Stat3 expression (250). In mast cell neoplasms the expression 
of mir-539 and mir-381 is reduced by KIT signaling and subsequently the target MITF is 
upregulated contributing to cell proliferation. (251). KIT is also the target of mir-193a (252). 
Mir-193a was found to be repressed in KIT mutated blast cells and when the expression was 
restored or mimicked the KIT expression was reduced and cell growth inhibited. 
 
  21 
2 THE PRESENT STUDY 
2.1 AIM 
The overall aim of the study presented in this thesis was to investigate mast cell function in 
health and disease. 
The specific aims for papers I-VI were: 
Paper I: To study the in vivo reactivity of mast cells in patients with systemic mastocytosis. 
Paper II: To investigate the in vitro reactivity and genetics of mast cells developed in vitro  
from progenitor cells enriched from patients with systemic mastocytosis. 
Paper III: To analyze the sensitivity of KIT mutated mast cells to combinatorial treatment 
with ABT-737 and Roscovitine. 
Paper IV: To explore the effect of the deacetylase inhibitor SAHA on a KIT mutated cell line 
and primary bone marrow cells. 
Paper V: To examine the dependence of Bfl-1 for activation-induced mast cell survival. 
Paper VI: To reveal the in vivo function of the pro survival gene A1. 
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2.2 MATERIAL AND METHODS  
The methodology used in the study is briefly described herein. For a more detailed 
description please see papers I-VI. 
Chromatin immunoprecipitation 
ChIP assay was performed by crosslinking the chromatin to regulatory proteins using 
formaldehyde. The isolated nucleus was shredded and protein modifications of interest were 
extracted with bead separation. DNA was released from the protein and analyzed with PCR. 
Basophil Histamine release assay 
Blood donated from patients and health subjects were washed and incubated on the assay 
plates coated with anti-IgE for 30 minutes at 37°C before the plates were washed and sent to 
RefLab Aps for analysis on the Histareader™ 
Enzyme linked Immunosorbent assay (ELISA) 
ELISA was used to measure the release of prostaglandin D2 from human cultivated mast cells 
and to measure the release of murine mast cell protease 1 and 2.  
Flow cytometry 
Flow cytometry was used in most studies to analyze surface receptor expression using 
monoclonal antibodies with conjugated flourophores. It was also utilized in investigating the 
cell vibality by staining the cells with propidium iodine and AnnexinV.  
Histamine assay 
Supernatants from activated mast cells was incubated on the assay plates at 37°C for 30 
minutes before the plates were washed and sent to RefLab Aps (Copenhagen, Denmark) for 
analysis on the Histareader™ 
Histology 
Human tissue samples were taken using a 3 mm disposable punch, under local anaesthesia. 
Samples were snap frozen, embedded immediately in TissueTek OCT medium and stored at 
70°C. For staining, 6 mm thick sections were cut by cryostat. Tryptase containing cells were 
visualized using Z-Gly-Pro-Arg-4-methoxy-2-naphthylamide and Fast Garnet GBC. The 
protein of interest was stained immunohistochemically. Murine tissue specimens were fixed 
with paraformaldehyde and embedded in paraffin. Four-micrometer sections were stained 
with toluidine blue and fast green for histological examination and enumeration of mast cells 
In vitro cultures of human mast cells 
Peripheral blood mast cells were developed from whole blood donated by healthy controls or 
subjects recruited via the Mastocytosis center Karolinska where they were clinically 
evaluated. The CD34+ cells were separated using magnetic bead separation and were 
cultured for approximately seven weeks under both hypoxic and normoxic conditions with a 
cocktail of cytokines including SCF, IL-6, IL-9 and IL-4, as described by Lappalainen et al 
(253). At the end of the culture period the maturation of the cells was determined by 
enzymatic staining for tryptase activity. Cord blood derived mast cells were cultured from 
donated umbilical cord blood. Progenitor cells were cultured in StemPro medium 
supplemented with IL-3, SCF and IL-6. All participants were informed and provided their 
written informed consent to participate. 
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In vitro culture of murine mast cells 
Connective tissue mast cells were derived from bone marrow by culturing the cells in RPMI 
1640 with supplemented with FBS, L-glutamine, sodium pyruvate, nonessential amino acids, 
penicillin, streptomycin, 2-ME, SCF and murine IL-4. Mucosal-like mast cells were produced 
by culturing bone marrow cells in DMEM with FBS, L-glutamine, sodium pyruvate, 
penicillin, streptomycin, SCF, human TGF-β1, murine IL-9 and murine IL-3. Peritoneal cell–
derived mast cells were generated by cultivating peritoneal cells in Opti-MEM complemented 
with FBS, L-glutamine, penicillin and SCF containing hybridoma supernatant harvested from 
CHO-KL cell cultures or murine SCF. 
Mast cell activation 
Mast cells both human and murine were activated for 30 min at 37°C before the reaction was 
stopped on ice. IgE-receptor activation was performed by incubating the human mast cells 
with IgE for 24 hours before being washed and anti-IgE was added. They were also activated 
with ionophore A23187, Morphine and Mannitol. Murine mast cells were sensitized with IgE 
by incubation with 15% hybridoma supernatant containing 1 mg/ml monoclonal mouse anti–
2,4,6-trinitrophenol (TNP) IgE Ab (IgEl-b4; American Type Culture Collection) for 90 min. 
The cells were then stimulated with 100 ng/ml TNP-BSA or ionomycin alternatively 
ionophore A23187. The supernatants were spun down and stored at -70°C until time for 
analysis. 
Mast cell lines 
The human mast cell lines HMC-1.1 and HMC-1.2 (were maintained in IMDM (Sigma) 
supplemented with 10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin/streptamycine and 1.2 
mM monothioglycerol (254, 255). The human mast cell line LAD-2) was maintained in 
supplemented StemPro-34 SFM medium with 100 ng/ml SCF (256). 
Measurement of mast cell mediators in blood and urine 
Serum tryptase levels were measured with the ImmunoCAP® tryptase assay. The major 
urinary histamine metabolite tele-MIAA was measured by LC/MS and values were expressed 
as micromole per milimole creatinine (257). The early PGD2 metabolite, 11β-PGF2α, was 
measured in urine using a commercial enzyme immunoassay kit (Cayman Chemical Co., 
Inc., Ann Arbor, MI). Urine creatinine concentrations were measured by automated 
colorimetric Jaffe method.   
Methacholine and Mannitol provocation test  
Methacholine (MCh) (prepared at Karolinska University Hospital Pharmacy, Stockholm, 
Sweden) inhalation challenges were performed using a dosimeter-controlled jet nebulizer 
(Spira Electro 2; Respiratory Care Center, Hämeenlinna, Finland). For Mannitol provocation 
test, mannitol capsules (Aridol, Pharmaxis, Frenchs forest, NSW, Australia) were inhaled 
using a dry powder inhaler (Plastiape, Osnago, Italy). The challenge was initiated with an 
empty capsule and FEV1 was measured in duplicates 60s later. If the fall in FEV1 was <10% 
from baseline value, challenge proceeded, commencing with 5 mg of mannitol. Spirometry 
was performed 60s later and if the fall in FEV1 was < 15%, the dose of mannitol was 
increased stepwise (10, 20, 40, 80, 160, 160, 160 mg) until the fall in FEV1 was >15% or the 
maximum cumulative dose (635 mg) according to the protocol had been administered. 
microRNA analysis 
RNA was extracted using Trizol though isopropanol was exchanged for ice-cold absolute 
ethanol. The RNA was treated with heparinase for two hours at 25°C and then analyzed with 
qPCR or with Affymetrix® miRNA array 2.0 at the core facility for bioinformatics and 
expression analysis, Karolinska Institutet. 
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Passive cutaneous anaphylaxis 
Mice under anesthesia and analgesia were sensitized passively with IgE by intradermal 
injection in the ear pinnae of DNP-specific IgE antibodies or with PBS and were challenged 
24 hours later by intra venous injection with DNP. Ear swelling was measured immediately 
before and at 30-min intervals after antigen challenge for 6 h using a micrometer. 
Passive systemic anaphylaxis 
Mice were sensitized passively with IgE by intra peritoneal injection of DNP-specific IgE 
antibodies in PBS and then challenged 24 hours later with DNP in PBS. Body temperature 
was measured directly before and at 5-min intervals after antigen challenge for up to 1 hour. 
Quantitative polymerase chain reaction 
RNA was translated into cDNA by reverse transcription. The cDNA was amplified using 
gene specific primers that were either purchased ready-made or designed using Primer3+.  
Reduction of gene expression using small interfering RNA 
Cells were transfected using a gene specific siRNA pool with five siRNAs targeting different 
sequences in the target RNA. siRNA was introduced using an Amaxa Nucleoporator. 24 
hours post transfection dead cells were removed and the effect on gene inhibition was 
measured with qPCR. 
Serum concentration of IgE 
The serum concentrations of IgE (kE/L) were determined with (ImmunoCAP® Total IgE, 
ThermoFisher, Uppsala, Sweden). The specific IgE antibody test (ImmunoCAP® Phadiatop®, 
ThermoFisher) was applied in six patients. 
Skin prick test 
Skin prick testing (SPT) was performed with commercial extracts of standard aeroallergens 
(birch, timothy grass and mugwort pollens, cat, dog and horse dander, house dust mites, 
moulds) and food allergens (milk, egg, nuts, cereals, codfish, shrimp), and hymenoptera 
venom (bee and wasp). Additionally, SPT with the MC secretagogues morphine (10 mg/ml) 
was performed. As a positive and negative control we used histamine dihydrochloride 
10mg/ml and saline (NaCl 0.9%), respectively. A skin test panel was considered positive if 
the wheal diameter was at least 3 mm larger than that elicited by the saline control. 
Statistical analyses 
The statistical analyses were performed using GraphPad Prisim version 5 and differences 
were considered significant if p<0.05. All data have been presented as mean and SEM unless 
otherwise stated. Commonly student T-tests were used in two group comparisons and two-
way ANOVA with bonferroni posttest was used in multiple group comparisons. 
Study subjects  
In study I and II, 15 cases (≥18 years) with systemic mastocytosis (5 men and 10 women), 
with a median age of 48 years (21 to 69) were recruited. 13 healthy volunteers (eight women, 
five men), aged 22 to 55 years with no history of allergic diseases, and 11 subjects with 
allergic asthma (eight men, three women), aged 22 to 52 years constituted the control groups 
for the study. Exclusion criteria were usage of beta blockers; inability or refusal to undergo a 
bone marrow biopsy and aspirate, subjects with HIV or other known immunodeficiency, 
carcinoid syndrome, pheocromocytoma, pregnancy. 
Transgenic mice 
VVA1 and VVFF transgenic mice were generated by Dr Ottina at Innsbruck medical 
university (258). In our studies mice with a C57BL6 background was used. 6-12 old mice 
were used during the experiments according with Austrian legislation (BMWF-66.011/ 
0112II/3b/2012). 
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Western blot 
Cell lysate was separated with gel electrophoresis and transferred to a membrane where 
proteins were visualized using specific antibodies. 
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2.3 PAPER I; ANALYSIS OF IN VIVO MAST CELL REACTIVITY IN PATIENTS 
WITH SYSTEMIC MASTOCYTOSIS. 
Patients with systemic mastocytosis suffer from mediator related symptoms and in more 
severe cases organ failure due to mast cell infiltration.  One hypothesis is that individuals 
with systemic mastocytosis have mast cells with a more reactive phenotype, though this has 
never been proven scientifically. The aim of this study was to investigate whether patients 
with systemic mastocytosis have altered mast cell reactivity in vivo and/or if the target tissues 
have developed resistance to the circulating mast cell mediators. In this study we used two 
controls groups, healthy non-atopic controls and allergic asthma, the latter in order to 
compare to another mast cell associated disease. First we analyzed baseline levels of serum 
tryptase and the urinary metabolites of histamine, 1-methyl-4-imidazoleacetic acid (tele-
MIAA) and the PGD2 metabolite 11β – PGF2α. We also examined the histamine release 
from basophils, since the functionality of basophils in SM has previously not been examined 
and these cells could be a potential source of histamine. To investigate the reactivity of the 
target tissues we evaluated whether tissue responsiveness was altered in SM patients by skin 
prick test with morphine and histamine; and provocation with mannitol and methacholine of 
the airways. 
 
Figure 5, Serum and urinary analysis of histamine, tryptase and PGD2. A) Urinary 
levels of the major histamine metabolite tele-MIAA. B) Baseline serum tryptase levels (sBT). 
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C) Urinary levels of 11β-PGF2α, a metabolite of PGD2 in healthy controls and subjects with 
asthma or systemic mastocytosis (SM). The values presented are medians with interquartile 
ranges. D) Principal component analysis (PCA) of the relationships between tryptase, tele-
MIAA and 11β-PGF2α based on variance analysis, employing 62 urinary spot samples 
(performed in duplicate) and 31 serum samples. These variables were log-transformed and 
Pareto scaled. The extent of the variance explained by PC1 and PC2 was 79 and 14%, 
respectively. The extensive increase in their concentrations in some of the SM patients is 
reflected in the spread along PC1 axis. The SM patients formed a cluster that was clearly 
distinguishable from both the patients with asthma and the healthy controls. 
Serum tryptase as well as the urinary metabolites of histamine tele-MIAA and PGD2 11β – 
PGF2α, were significantly increased in patients with SM compared to the controls and 
formed a distinct group in a principal component analysis (Figure 5). Both patients with SM 
and controls showed an increase of release of histamine from basophils in a dose dependent 
way, however, there were no discernible differences between the groups. For the skin prick 
test we could not detect any differences between the groups, neither in response to morphine 
or histamine.  Likewise there was no indication of increased airway reactivity in patients with 
SM, i.e., no increase in airway responsiveness to mannitol or methacholine. 
In this study we demonstrate that patients with systemic mastocytosis have increased 
systemic levels of mast cell mediators, as previously described. Even so when mast cell 
stimulus was applied locally, in the skin and airways, there were no discernable differences in 
response between the groups. One hypothesis was that the end organs have somehow 
developed a resistance to the mediators. But when a pure mast cell mediator, i.e., histamine, 
was added locally to the skin, or methacoline was inhaled, the same response was recorded in 
individuals with systemic mastocytosis as in the control groups. It is well known that patients 
with mastocytosis have increased levels of circulating mast cell mediators. Since we could 
not provide data supporting the hypothesis of a hyperactive mast cell phenotype in systemic 
mastocytosis one interpretation of the data is that the increase in mast cell mediators is due to 
the increased number of mast cells. However, there might be a dysfunctional regulation of 
biosynthesis, storage or release of the mast cell mediators. Furthermore, we have in this study 
only investigated mast cells in the skin and in the airways, whereas SM patients are more 
prone to cardiovascular effects of mediator release rather than respiratory effects. Thus 
reactivity among mast cells might differ in different tissues in SM. Furthermore, SM patients 
are more prone to MC activation events following physical stimuli such as friction, 
temperature changes and exercise rather than pharmacologic stimuli.  
In conclusion we show that patients with systemic mastocytosis do no exhibit mast cell 
hyperreactivity in vivo. Neither is there evidence of a tissue resistance development as 
assessed by challenge with histamine or methacholine. Furthermore, no evidence of increased 
basophil reactivity was detected in these patients.  Our results suggest that the increased 
levels of mast cell mediators are due to the increase in mast cell numbers, but other 
dysfunctions in mediator synthesis, storage and release, or mast cell reactivity to other type of 
stimuli cannot be ruled out. 
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2.4 PAPER II; MAST CELLS FROM PATIENTS WITH MASTOCYTOSIS SHOW 
ALTERED MIRNA PROFILE AND OSMOTIC INDUCED HYPERREACTIVITY 
Paper II is another arm of the study on systemic mastocytosis. Whereas we in paper I 
investigated mast cell reactivity in vivo, in this part, paper II, we investigated mast cells in 
vitro. Here we aimed to further investigate the possibility of a hyperreactive mast cell 
phenotype and discern genetic differences beyond the KIT D816V mutation. Mast cells were 
developed in vitro from enriched CD34+ cells cultured in a cocktail of cytokines, including 
SCF. When cultures had reached a level of 90% tryptase positive cells, approximately seven 
weeks in culture, they were considered ready to be used. All patients with systemic 
mastocytosis carried at time of diagnosis mutated KIT in the bone marrow cells. However 
PCR specific to the D816V mutation revealed that none of the mast cell cultures harbored the 
mutation, suggesting that the CD34+ progenitor cells are D816V KIT negative. There were 
no differences between the groups in regard to the number of cells obtained at the end of the 
culture period. Surface expression of the FcεRI receptor was analyzed using flow cytometry 
and there was a trend pointing to increased expression of the receptor on cells from SM 
patients. We could not detect any differences between the groups in regard to the levels of 
histamine released after activation with calcium ionophore A23187, anti-IgE, morphine or 
mannitol (Figure 6 A). However the cells from the SM patients released significantly more 
PGD2 after activation with mannitol indicating a hyperactive cell type in response to 
alteration in osmolarity (Figure 6 B).  
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Figure 6. Release of histamine and PGD2 from activated in vitro developed mast cells. 
Mast cells were treated for 30 minutes with calcium ionophore A23187, morphine, mannitol 
or anti-IgE and the release of histamine (A) and PGD2 (B) was measured in the cell free 
supernatant. Healthy controls (open boxes)(n=6) and systemic mastocytosis (filled 
boxes)(n=11).  
Total RNA was analyzed on an Affymetrix ® miRNA array 2.0 to investigate the expression 
of 4544 noncoding RNAs in mast cells developed from SM patients and healthy controls, 
respectively. 13 miRNAs were identified with significantly different expression (p=0,001, 
q=0,36), either upregulated or down regulated, in cells from SM patients n=4 compared to 
healthy control n= 3 (Figure 7 A). Interestingly all of the miRNAs proved to have targets 
within the KEGG pathway of inflammatory mediator regulation of Transient Receptor 
Potential (TRP) channels. The subfamily of TRPV has been shown to contribute to how the 
nervous system is able to detect changes is osmolarity (259, 260). We further analyzed the 
mRNA on the  of three patients and two controls in order to narrow down the possible 
miRNA targets using the PrimeView™ Human gene array (Figure 7 B). It resulted in 47 
differentially expressed mRNAs. Four miRNAs had numerous targets within the deregulated 
mRNAs. The antisense RNA of the gene ABCC5 is a target of three of the upregulated 
miRNAs and is significantly down regulated in the patients (Figure 7 C). This antisense RNA 
has the ability to bind to the mRNA of ABCC5 and obstruct the receptor expression on the 
cell surface. Furthermore, ABCC5 is a member of a family of transporter proteins known to 
be responsible for the exodus of prostaglandins (261). 
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Figure 7. miRNA and mRNA expression in in vitro developed mast cells. (A) miRNA 
expression (B) mRNA expression C) mRNAs with target sequences for the detected 
miRNAs. 
 
In conclusion we show that mast cells cultured from progenitors retrieved from patients with 
mastocytosis release significantly less PGD2 then control cells. Analyzing the RNA we found 
a specific miRNA and mRNA profile for Mastocytosis. The deregulation of ABCC5 may 
explain the differences in PGD2 release.    
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2.5 PAPER III; ABT-737 AND ROSCOVITINE INDUCES APOPTOSIS IN A 
SYNERGISTIC FASHION IN MAST CELLS CARRYING THE D816V 
MUTATION 
Systemic mastocytosis is characterized by the accumulation of aberrant mast cells with D81V 
KIT mutation. The D816V KIT mutation renders the receptor to be phosphorylated and the 
downstream signaling pathways continuously activated. One effect of this autoactivation is 
the increased expression of the prosurvival members of the Bcl-2 family , a family of proteins 
which are the main regulators of cell survival (190). In this study we examined the effect of 
combinatorial treatment of KIT D816V positive mast cells with ABT-737 and Roscovitine. in 
order to target most of the pro survival Bcl-2 family members. ABT737 is a BH3-mimetic 
which inhibits Bcl-2, Bcl-XL and Bcl-w. Our group has previously shown that it ABT737 
induces apoptosis in cutaneous mast cells (178). Roscovitine is a CDK-inhibitor that also 
downregulate the expression of prosurvival Mcl-1 (262). 
We found that ABT-737 and Roscovitine both alone and in combination induced apoptosis in 
D816V positive HMC-1.2 mast cells (Figure 8). The cells were treated for 24 and 48 hrs with 
Roscovitine 10 or 30 µM, ABT 0.05 µM  or the combination of the two (ROS 10 µM  and 
ABT 0.05 µM). The combination of the drugs at suboptimal concentrations induced a marked 
reduction in cell viability. The combinatorial treatment reduced the expression of Mcl-1 and 
significantly upregulated the expression of proapoptotic BimEL.  
 
Figure 8. Low doses of ABT-737 and Roscovitine exhibit synergistic effects in inducing mast cell 
death. HMC-1.2 cells were treated with Roscovitine, ABT-737 or the combination of the two.  
Survival was measured after 24 and 48 hrs (top); the levels of BIMEL and Mcl-1 were measured after 
48 hours (bottom).  
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In conclusion we demonstrate that the antiapoptotic proteins of the Bcl-2 family are 
promising targets in the treatment of systemic mastocytosis. By combining the two drugs, in 
order to target most of the different pro-survival proteins, the doses can be reduced 
significantly. This would reduce the risk of severe side effects, increase the treatment efficacy 
and may hinder the development of drug resistance. 
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2.6 PAPER IV; HISTONE DEACETYLASE INHIBITOR SAHA MEDIATES MAST 
CELL DEATH AND EPIGENETIC SILENCING OF CONSTITUTIVELY 
ACTIVE D816V KIT IN SYSTEMIC MASTOCYTOSIS 
The aim of this study was to investigate the effect of the histone deacetylase inhibitor SAHA 
on mast cells with D816V mutation. HDAC inhibitors (HDACi) are small molecules that 
prevent the enzymatic removal of acetyl groups from the N-terminal tails of histones. SAHA 
is a pan inhibitor altering the expression of 5-15% of protein coding genes; approximately 
same number of genes are up and down regulated (263). SAHA is currently approved for the 
treatment of cutaneous T-cell lymphoma and in addition presently in numerous clinical trials. 
Previous studies in other cellular systems indicate that the KIT receptor is a promising target 
of SAHA (264).  
In this study we analyzed the effect of SAHA as well as other HDACi Romidepsin, 
Panobinostat and Valproic acid on the human mast cell line HMC-1.2 which carries the 
D816V KIT mutation. All four drugs induced apoptosis and reduced cell proliferation in a 
dose dependent fashion. The most extensive effect was achieved with SAHA treatment. 
Analysis of KIT receptor expression revealed a decrease in both mRNA levels and surface 
expression as well as in receptor phosphorylation.  
Knowing that the cells die and that the mutated receptor is targeted we continued to 
investigate the effect on fresh bone-marrow samples from patients with different forms of 
systemic mastocytosis. SAHA treatment had a profound effect on the bone marrow cells and 
the efficacy of the drug correlated to the severity of the disease (Figure 9).  
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Figure 9.Response to SAHA treatment in in mast cells isolated from bone marrow. A) Flow 
cytometry gating strategy for side scatter (SSC) and KIT expression (CD117), example of gating for 
CD117 positive cells. B) Staining of patient sample bone marrow mast cells upon incubation with 
SAHA for 48 h.  C) Decrease in surface KIT in patients vs controls D) Mast cell viability after 48h of 
SAHA treatment.  
To further investigate the mechanistic effect we examined the epigenetic stability of the 
genomic region around the KIT gene, focusing on the regulatory region as well as the genes 
up (KDR) and downstream (PDGFRα) of KIT. Using the active marks H3K18ac and 
H3K27ac and repressive marks H3K9me3 and H3K27me3 we could discern that in the KIT 
mutated cell line HMC-1.2 the KIT region is active already at baseline but the activation was 
significantly reduced with SAHA treatment (p<0.05 for -71, p<0.01 for -123 and KIT promoter 
region) (Figure 10). The surrounding genes though were silent at baseline but were activated 
with SAHA.  
 
 
 
Figure 10. ChIP qPCR of HMC1.2 cells with active and repressive histone H3 marks, corrected 
for H3 density over the KIT region. A) H3K27me3 repressive mark. B) H3K9me3 repressive mark. 
C) H3K27ac active mark. D) H3K18ac/H3 active mark.E) Illustration of the region and primers 
Genes in the region 
Primer location 
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In this study we show that the HDAC inhibitor SAHA is very effective at inducing apoptosis 
in aberrant mast cells because the KIT region is silenced at an epigenetic level. The 
mechanistic need to be further elucidated, but we suggest that SAHA should be considered in 
the treatment of the more aggressive cases of mastocytosis.  
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2.7 PAPER V; ANTI-APOPTOTIC BFL-1 IS THE MAJOR EFFECTOR IN 
ACTIVATION-INDUCED HUMAN MAST CELL SURVIVAL 
Mast cells are long lived tissue residing sentinels. In order to keep this function they need the 
capacity not only to survive the massive cellular rearrangement of degranulation but also to 
swiftly reform and restock the granules (89). Our group has previously demonstrated that the 
antiapoptotic protein Bfl-1/A1 is upregulated in activated mast cells and that mouse mast 
cells lacking the A1 gene do not exhibit activation induced survival (197). In this study we 
investigated the role of Bfl-1 in human mast cells to decipher if this is the main regulator of 
activation-induced mast cell survival.  
ABT-737 and Roscovitine failed to hinder activation induced survival following IgE cross 
linking indicating that neither Bcl-2, Bcl-XL, Bcl-w nor Mcl-1 are major regulators. However 
by inhibiting the expression of t Bfl-1 using siRNA the mast cells did not exhibit activation-
induced survival (Figure 11). To translate these data into an in vivo situation we examined the 
Bfl-1 expression in mast cells. In allergen provoked skin of allergic subjects we found a 
significant increase in the mast cell expression of Bfl-1 in the allergen challenged skin. 
Interestingly there was also an increase of Bfl-1 expressing mast cells in lesional skin of 
patients suffering from atopic dermatitis and psoriasis. Those diseases are not associated with 
IgE- receptor crosslinking but mast cells can also express IgG-receptor FcγRI and activation 
through this also induces a similar survival program in mast cells (203).  
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Figure 11, Bfl-1 regulate activation induced survival and is upregulated in atopic skin. 
A) siRNA inhibit upregulation of Bfl-1 and Mcl-1. B) Silencing of Bfl-1 inhibit the increase 
of viability following IgE crosslinking. C) Co-staining of tryptase and Bfl-1 in atopic skin.  
 
In conclusion, in this study we demonstrate that Bfl-1 is the main regulator of activation- 
induced mast cell survival after IgE-receptor crosslinking. Since there was an increased 
expression of Bfl-1 in the mast cells in the provoked skin of patents with allergic disease we 
propose that Bfl-1 can be responsible for the increase in mast cell number and thus can serve 
as a therapeutic target for some groups of patients with cutaneous inflammatory diseases.  
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2.8 PAPER VI; KNOCKDOWN OF THE ANTI-APOPTOTIC BCL-2-FAMILY 
MEMBER A1 PROTECTS MICE FROM SYSTEMIC ANAPHYLAXIS 
In this study we continued to investigate the function of A1 in mast cell development and 
survival, and for mast cell driven reactions in vivo. Our previous studies showed that A1/Bfl-
1 is an important regulator of mast cell survival however the in vivo significance is poorly 
investigated. Due to the genetic location of the three A1 isoforms no traditional A1 knockout 
mouse has been possible to create. Ottina et al developed a constitutive knockdown of all A1 
isoforms in the hematopoietic system by RNA interference (258). 
Mast cells are highly heterogeneous but how the differences are regulated is poorly 
understood. Murine mast cells are generally divided into mucosal and connective tissue mast 
cells. They are located at different tissues and express diverse proteases. They are very 
diverse in their development and survival. Connective tissue mast cells are long lived and 
tissue resided. Mucosal mast cells are quickly recruited into the tissue after a helminth 
infection though only survives for a few weeks. 
Mucosal like and connective tissue like mast cell were cultured and the RNA interference 
was stable during the cultivation. The mucosal like mast cells did not appear to depend on A1 
for survival and differentiation. The connective tissue like mast cells on the other hand 
showed impaired mast cell survival after IgE-receptor crosslinking, similarly to previously 
described (201). The number of connective tissue mast cells in vivo were significantly 
reduced in ears and tongues of A1 knockout mice.  
Both passive systemic and cutaneous anaphylaxis was severely reduced in mice lacking 
A1expression and there was a significant reduction of mast cells in the dermis of the ear 
pinnae after passive cutaneous anaphylaxis (Figure 12). In passive cutaneous anaphylaxis 
DNP-specific IgE was injected into the ear pinnae (WT n=6, VVFF control n=7 and VVA1 
n=5), after 24h the mice were challenged by i.v injection of the DNP and ear swelling was 
investigated every 30 min for 6 hours. After 6 hours the number of mast cells in the ear 
pinnae was investigated and there were significant differences in mast cell numbers. 
Interestingly when peritoneal mast cell from A1 knockout mice were cultured in vitro we 
found that they do not proliferate at the same rate as the control samples. 
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Figure 12. A1-knockdown mice exhibit markedly reduced IgE-dependent cutaneous 
PCA. A) Passive cutaneous anaphylaxis, ear swelling was measured immediately before 
and at 30-min intervals after Ag challenges for 6 h. B) Numbers of mast cells in the dermis 
of ear pinnae at sites of PCA 6 h after DNP challenge. C) Representative toluidine blue 
staining of activated mast cells in ear pinnae. Arrows indicate mast cells. 
 
Mice which lack A1 expression do not respond to activation of the FcεRI receptor via IgE 
crosslinking to the same extent as control mice. They also have fewer mast cells in the tissue 
and interestingly mast cells recovered from the peritoneal cavity display impaired 
proliferation. To conclude we demonstrate that A1 is an important regulator in the 
development of connective tissue mast cells an important step in the understanding in mast 
cell heterogeneity. 
.  
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3 FUTURE PERSPECTIVE 
Though the mast cell was discovered in 1878 there are so many things we do not understand 
about them. The first hundred years they were mostly regarded as effector cells in allergic 
diseases. Currently though they are well recognized as an important part of the body’s host 
defense system. In this thesis I describe the work I have done to understand the mechanisms 
of mastocytosis, identifying a cure and to understand mast cell development and survival. 
Mastocytosis a rare disease but it is well worth to study. To me one of the most puzzling 
questing is exactly how the point mutation develops? Mastocytosis is not a hereditary disease 
though a few cases of familiar mastocytosis had been described. And most patients with 
systemic mastocytosis carry the same point mutation though in different compartments. So 
why this exact locus? What is it with this small genetic region that make different, unrelated 
people all around the world acquire the same exact mutation? Point mutations generally occur 
during replication but they can also be the result of DNA damage. Recent studies highlight 
the correlation between epigenetic changes and DNA mutations. The epigenetic network of 
DNA and histone modifications modify the DNA accessibility but also the genetic stability. 
TET2 along with other genes involved in DNA methylation have been shown to be mutated 
in mastocytosis by many groups. Also the general levels of DNA methylation has been 
shown to be reduced. We know from other neoplastic diseases that point mutations often 
occur at CpG sites. For this reason it would be interesting to investigate the epigenome of 
mast cells from patients with mastocytosis. To backtrack the cells from the mature mast cells 
back to the progenitor cells and study the DNA for mutations as well as alterations in the 
DNA stability and histone status. The D816V mutation is a founding event but perhaps the 
chain stats before that, with a slight shift in DNA stability? 
By increasing our understanding of the disease we may find new ways to treat the patients. At 
the moment different lines of therapies are being investigated; targeting the KIT receptor, 
inhibiting downstream pathways of KIT, utilizing surface molecules etc. Many of the drugs 
have severe side effects. Combinational treatments where drugs increase the efficacy by 
synergistically target parts of the same pathway is a way to reduce the drug dose which 
should reduce the side effects. For example a TKI could be combined with one or more 
molecular inhibitors. Within the field of TKI development many new KIT specific drugs are 
emerging however they have all different effects of the different KIT mutations. In the future 
of personalized medicine the analysis of the patient mutational status could direct the 
treatment.  
Mast cells are very heterogeneous their development entirely dependent of the release of 
cytokines from the surrounding tissue. This is a complex event activating multiple pathways 
and finally producing proteins to execute the receptor signals. Which proteins are expressed 
is largely depending on the epigenetic landscape of the cell. We have just started to scrape the 
surface on how mast cell development is regulated by epigenetic changes. Recently Damiani 
et al showed that platelet activating factor alter the expression of DNA methyltransferases1 
and 3b (265). At the same time the expression of histone acetyltransferase increases as do the 
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H3acetlyation. It is probable that similar events occur after activation of other cytokine 
receptors. Receptor stimulation leads thus to the opening of genes. It would be interesting to 
investigate how different stimuli alter the epigenetic genome and how that change gene 
transcription. It would also alter the transcription of noncoding RNAs. The latest study shows 
that there are almost four thousand miRNAs in the human genome but only a handful of them 
have been implicated in mast cell biology (266). Even fewer of them have been functionally 
studied but those investigations prove that miRNAs are vital in mast cell development in 
health and disease. Long noncoding RNAs (lncRNAs) are ten times longer than miRNAs and 
by far more numerous about the same numbers as of protein coding genes. They regulate 
gene transcription at multiple levels and by different mechanisms. For example by actively 
cooperate in transcriptional complexes and by binding and by inhibiting the mRNA produced 
however. Only a few lncRNAs have been characterized and studied in detail and next to 
nothing is known about lncRNAs and mast cells. There are some studies showing lncRNA 
influencing hematopoiesis by affecting transcription factors like GATA1 and TAL-1 both of 
which are important in mast cell development. A quick enquiry reveals there are 3 lncRNAs 
placed in the KIT gene. Their expression and function would be very interesting to 
investigate.  
There are many interesting lines of enquiry in the field of mast cell biology which are worth 
investigating. However I find that most new breakthroughs come after the development of 
new methods. Therefor it is hard to imagine what awaits around the corner. The 
implementation of the CRISPR/Cas9 technique into mast cell research will expose new 
frontiers. The first studies applying it in mast cell biology revealed the importance of 
carbonic anhydrase enzymes in mast cell development (267). 
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